Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center


Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCDERM1059


Phase IV Randomized Study of Two Dose Levels of Targretin Capsules in Patients with Refractory Cutaneous T-Cell Lymphoma

Principal Investigator(s)

John Zic


  • Protocol No. VICCDERM1059
  • Open Date: 06/01/2011
  • Staging: Phase IV
  • Age Group: Adults
  • Scope: National
  • Objective: To evaluate the efficacy, safety and tolerability of two initial dose levels of Targretin capsules in patients with refractory CTCL
  • Disease Sites: Lymphoma
  • Therapies: Chemotherapy - cytotoxic
  • Drugs: Bexarotene
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: E7273-G000-401


None Provided.


Not provided. Please call for more information.